Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
Direct focus on oncology therapies (lead candidates RP-3467 and RP-1664) and the SNIPRx platform positions Repare as a biotech oncology company.
|
$77.20M |
$1.80
-1.10%
|
|
IGM's business rests on an engineered IgM antibody platform, a distinct discovery platform for novel antibody therapeutics.
|
$76.35M |
$1.27
|
|
Quince Therapeutics is focused on a rare pediatric neurodegenerative disease (Ataxia-Telangiectasia) with its lead asset and platform, fitting the Rare Diseases biotech theme.
|
$75.02M |
$1.65
+0.61%
|
|
Develops immunology/immune-oncology therapeutics (conditioned activation cytokines and T-cell engagers).
|
$73.14M |
$1.63
-9.94%
|
|
Lead candidate CardiolRx is a cardiovascular drug targeting myocarditis and recurrent pericarditis, placing Cardiol Therapeutics in the Cardiovascular Drugs investable theme.
|
$73.00M |
$1.04
-4.59%
|
|
Company pursues cancer treatment platforms and immunomodulatory approaches, aligning with oncology biotechnology.
|
$71.79M |
$2.10
|
|
Core oncology-focused biotechnology developing targeted therapies (SMARCA2 degraders, KAT6A degraders, and antibody-drug conjugates).
|
$71.14M |
$1.26
-9.35%
|
|
Lead program neflamapimod is an orally administered small molecule, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$70.93M |
$8.15
-5.12%
|
|
Company is a biotechnology focused on oncology, explicitly described as developing cancer therapies.
|
$70.66M |
$1.38
|
|
Lead oncology asset Plinabulin positions BeyondSpring in cancer therapeutics, aligning with Biotech - Oncology.
|
$70.15M |
$1.74
-4.92%
|
|
Cadisegliatin (TTP399) is an oral small molecule therapeutic in development by vTv Therapeutics, fitting the 'Oral Small Molecule Therapeutics' category.
|
$69.84M |
$21.86
|
|
Directly develops NXC-201, a sterically-optimized CAR-T cell therapy, which is a cell therapy platform.
|
$69.69M |
$2.50
-7.41%
|
|
Directly develops AlloNK allogeneic NK cell therapy platform (AB-101) for autoimmune indications, a core cell therapy product.
|
$68.46M |
$2.81
-7.87%
|
|
Direct product category: Antibody-Drug Conjugates (ADC) therapies, including next-generation ADC programs.
|
$67.88M |
$0.80
-5.80%
|
|
NDV-01 and Sepranolone are drug candidates developed by Relmada in oncology and neuropsychiatry, aligning with Biotech - Oncology.
|
$67.71M |
$2.04
-8.93%
|
|
Rejuva gene therapy platform (RJVA-001/002) represents a gene therapy program delivering AAV to the pancreas for long-term metabolic control.
|
$65.63M |
$1.34
-5.63%
|
|
Biomea Fusion is developing and planning to commercialize oral small-molecule therapeutics (e.g., icovamenib, BMF-650) for metabolic diseases, which directly maps to the 'Oral Small Molecule Therapeutics' category.
|
$63.12M |
$1.68
-5.62%
|
|
ARCUS is a gene editing platform used for in vivo therapies, a core product/technology of Precision BioSciences, aligning with gene therapy as a major business segment.
|
$62.87M |
$5.67
+4.23%
|
|
MN-166 and MN-001 are explicitly described as orally available small molecule therapeutics, matching the 'Oral Small Molecule Therapeutics' tag.
|
$62.78M |
$1.28
+3.23%
|
|
First Defense provides passive immunoglobulin-based protection against calf scours, a vaccine-like immunization product for livestock.
|
$61.45M |
$6.80
+1.49%
|
|
Direct RNA-based therapeutics platform focusing on upregulating gene expression via regRNA-targeting antisense oligos.
|
$61.09M |
$3.03
+1.00%
|
|
Contract manufacturing services for OEMs, including electronics, aligning with outsourced manufacturing.
|
$60.87M |
$3.82
-1.80%
|
|
Cue Biopharma is developing oncology immunotherapies (CUE-101, CUE-102) using its Immuno-STAT platform.
|
$59.94M |
$0.80
-14.46%
|
|
Core oncology-focused biotech company delivering cancer therapies (ACR-368, ACR-2316) and diagnostics.
|
$59.89M |
$1.91
+1.60%
|
|
LENSai functions as an antibody discovery platform, directly aligning with MindWalk's core product.
|
$59.46M |
N/A
|
|
Genenta's core platform is gene therapy (hematopoietic stem cell gene therapy) targeting solid tumors.
|
$59.44M |
$3.25
-2.98%
|
|
DURECT's core offering is an oral small molecule therapeutic (larsucosterol) for alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
Company is a clinical-stage oncology biotech focused on immunotherapy and targeted cancer therapies.
|
$57.88M |
$1.57
-7.10%
|
|
Aligos develops small-molecule antivirals for HBV and pan-coronavirus infections, aligning with the Antiviral Small-Molecule Therapeutics investable theme.
|
$57.66M |
$9.43
-8.18%
|
|
GT-02287 is a small-molecule therapeutic candidate (category: Oral Small Molecule Therapeutics) in Phase 1/1b for Parkinson's disease.
|
$56.75M |
$2.23
+16.15%
|
|
OSTX's lead product OST-HER2 is an oncology immunotherapy based on a Listeria platform, directly constituting a cancer treatment product.
|
$55.91M |
$1.99
-5.24%
|
|
MiNK Therapeutics' core business is the discovery, development, and manufacturing of allogeneic, off-the-shelf iNKT cell therapies (cell therapy platform).
|
$55.80M |
$14.00
-4.24%
|
|
GEAR Cell Therapy Platform and SNAP-CAR assets are direct cell therapy products within oncology.
|
$55.17M |
$15.70
-1.94%
|
|
Direct focus on immunology/inflammation therapeutics via lead candidate VTP-1000 and the SNAP-TI immune-tolerance platform.
|
$54.86M |
$1.36
-4.90%
|
|
NRx's pipeline focuses on CNS/neuropsychiatric indications (suicidal depression, bipolar disorder), fitting Neuropsychiatric Drug Development.
|
$54.81M |
$3.17
-11.70%
|
|
Veru's lead products are oral small molecule therapeutics (enobosarm and sabizabulin), with enobosarm targeting weight loss and sabizabulin in late-stage ASCVD programs.
|
$54.68M |
$3.73
+3.61%
|
|
CNM-Au8 and the CSN platform represent a drug delivery platform that directly underpins the company's therapeutic products.
|
$54.35M |
$6.05
-1.14%
|
|
Kronos Bio's core activity centers on oncology therapeutics and transcription-targeted oncology programs, aligning with Biotech - Oncology.
|
$53.65M |
$0.88
+1.49%
|
|
VeriStrat and related Nodify tests function as biomarker-based diagnostics that inform treatment decisions (companion diagnostics).
|
$53.64M |
$7.32
-6.75%
|
|
OLC and UNI-494 are both oral, small-molecule therapeutics (phosphate binder and prodrug respectively), placing UNCY in the 'Oral Small Molecule Therapeutics' category.
|
$53.56M |
$4.44
-6.72%
|
|
Core POZ drug-delivery platform directly enabling long-acting, CNS-targeted therapeutics.
|
$52.93M |
$5.31
-0.38%
|
|
Mister Meds and RxCompound operate as pharmaceutical contract manufacturing capabilities (compounding).
|
$52.85M |
$0.18
-3.80%
|
|
Ifetroban is CPIX's lead pipeline candidate and is a small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$51.62M |
$3.45
-2.27%
|
|
ABVC's pipeline includes oncology-focused plant-derived therapeutics and cancer programs (e.g., ABV-1519 for NSCLC), aligning with Biotech - Oncology.
|
$50.99M |
$3.04
-7.03%
|
|
AKTX develops Antibody-Drug Conjugates (AKTX-101, AKTX-102) including novel payloads, targeting Trop2, i.e., direct ADC product category.
|
$50.76M |
$1.02
+11.90%
|
|
BioAtla is a biotechnology company focused on oncology therapies, fitting Biotech - Oncology.
|
$50.68M |
$0.87
-17.38%
|
|
JOTROL enables an oral small molecule therapeutic platform, a core product line for the therapeutic pipeline.
|
$50.65M |
$1.53
-3.77%
|
|
Lead asset Telomir-1 is described as an oral small-molecule therapeutic.
|
$49.11M |
$1.65
-7.82%
|
|
Adaptimmune directly develops engineered T-cell therapies (TECELRA, lete-cel, uza-cel) using a cell therapy platform.
|
$49.11M |
$0.18
-9.80%
|
|
Core Celularity business centers on allogeneic placental-derived cell therapies marketed as off-the-shelf products.
|
$49.10M |
$2.05
-3.76%
|
|
Century Therapeutics directly develops iPSC-derived allogeneic cell therapies (CAR-iNK, iT cells) and related platforms.
|
$49.00M |
$0.57
-5.22%
|
|
INKmune is a cell therapy platform (NK cell therapy), a direct Biotech - Cell Therapy product.
|
$48.97M |
$2.08
-1.18%
|
|
Nu.Q Cancer represents human oncology diagnostics, placing VolitionRx in the Biotech - Oncology space.
|
$47.81M |
$0.46
-10.75%
|
|
Inotiv is described as a fully integrated Contract Research Organization (CRO) providing nonclinical and analytical drug discovery and development services.
|
$47.75M |
$1.39
-6.08%
|
|
Karyopharm is a biotechnology company focused on oncology therapies, anchored by its cancer‑drug selinexor and SINE technology.
|
$47.52M |
$5.50
-6.94%
|
|
EQ001 (itolizumab) is a monoclonal antibody therapeutic, a core product category for EQ.
|
$47.51M |
$1.45
+9.02%
|
|
sEEG-based drug delivery system represents a drug delivery platform for localized therapeutic administration.
|
$47.33M |
$0.95
-7.77%
|
|
Lantern Pharma's core assets and clinical pipeline are oncology-focused, mapping to Biotech - Oncology.
|
$46.81M |
$4.34
-7.26%
|
|
Actinium's direct products are radiopharmaceuticals (ARC radiotherapies) such as Actimab-A and ATNM-400, and its pipeline centers on radiopharmaceutical oncology.
|
$46.48M |
$1.49
-1.97%
|
|
Company directly develops radiopharmaceuticals for diagnostic and therapeutic oncology applications.
|
$46.41M |
$7.03
-5.64%
|
|
Emi-Le (XMT-1660) is an antibody-drug conjugate (ADC) using the Dolasynthen platform.
|
$46.06M |
$9.24
+1.43%
|
|
ATH434 is a small-molecule therapeutic candidate (drug) in Phase 2 for MSA, fitting the 'Oral Small Molecule Therapeutics' category.
|
$45.65M |
$4.29
-1.38%
|
|
Provides contract research services related to gene-editing and trait development.
|
$44.36M |
$1.29
-0.77%
|
|
Auxora is a CRAC channel inhibitor, positioning CalciMedica as a provider of ion channel modulating therapeutics.
|
$44.22M |
$3.17
-6.36%
|
|
SNTI's core focus is oncology with immunotherapies and cell-based therapies, aligning with Biotech - Oncology.
|
$44.08M |
$1.69
-11.05%
|
|
Xilio's vilastobart is a monoclonal antibody therapeutic, directly aligning with Monoclonal Antibody Therapeutics.
|
$43.64M |
$0.84
-5.31%
|
|
Alopecia areata is a autoimmune/rare-disease area; bempikibart aligns with Rare Diseases focus as a disease-targeted biologic.
|
$43.55M |
$3.57
-0.56%
|
|
Company directly develops oncology-focused immunotherapies and platforms (Versamune HPV, PDS01ADC, Versamune MUC1) used to treat HPV-related cancers.
|
$43.30M |
$0.95
-5.27%
|
|
Buntanetap is an oral small-molecule therapeutic, the direct product category the company is developing.
|
$43.26M |
$2.22
-0.45%
|
|
Verrica's marketed product YCANTH (VP-102) for molluscum contagiosum establishes a dermatology pharma business with an ongoing pipeline, aligning with the pharma sector investable theme.
|
$43.19M |
$4.67
+2.41%
|
|
Life Sciences segment includes custom manufacturing (adenovirus production) services consistent with a CMOs.
|
$42.72M |
$36.01
|
|
FG-3246 is an antibody-drug conjugate (ADC) targeting CD46 for oncology.
|
$42.64M |
$10.55
-3.74%
|
|
Grace Therapeutics focuses on rare diseases with orphan designation across its pipeline (GTx-104, GTx-102, GTx-101), aligning with the Biotech - Rare Diseases investable theme.
|
$41.35M |
$2.99
-1.01%
|
|
Direct radioligand therapy modality using radioactive isotopes for targeted cancer treatment (RadioGel).
|
$40.84M |
$0.09
+0.90%
|
|
LAVA Therapeutics develops oncology therapies around its platform, placing it squarely in Biotech - Oncology.
|
$40.76M |
$1.55
+0.65%
|
|
The company directly markets and commercializes an ophthalmic bevacizumab product (ONS-5010/LYTENAVA) for retinal diseases, which is a clear ophthalmic drug product.
|
$40.28M |
$1.20
-2.44%
|
|
ctLNP/siRNA delivery platform enabling intracellular gene silencing in T cells for autoimmune indications (gene therapy modality).
|
$40.22M |
$5.72
-0.35%
|
|
Company focuses on discovery and development of oral small-molecule therapeutics powered by boron chemistry, with AN2-502998 for chronic Chagas disease and epetraborole for acute melioidosis, plus early oncology programs.
|
$39.23M |
$1.30
+2.36%
|
|
Lead programs are oral, small-molecule therapeutics (amezalpat and TPST-1495).
|
$38.30M |
$10.40
-2.07%
|
|
OTC Pain Relief & Analgesics private-label product line.
|
$37.68M |
$4.38
-8.68%
|
|
Dissolvable microneedle drug-delivery platform for skin cancer (Dermato-oncology) and the GnRH antagonist Teverelix for prostate cancer place Medicus Pharma squarely in oncology-focused biotechnology.
|
$37.07M |
$2.48
-3.13%
|
|
Preclinical oncology-focused biopharmaceutical company developing a high-affinity anti-CD47 antibody.
|
$36.68M |
$1.41
-9.03%
|
|
IO Biotech operates in oncology-focused biotechnology and its lead products are cancer vaccines.
|
$36.37M |
$0.55
-4.81%
|
|
Direct product briquilimab, a monoclonal antibody targeting the SCF/c-KIT axis for chronic urticaria, aligns with the Immunology Therapeutics category.
|
$36.05M |
$2.40
-3.23%
|
|
OT-101 is an RNA-targeted/antisense oncology therapeutic in late-stage clinical development.
|
$35.83M |
$0.09
-9.09%
|
|
Directly relates to cell therapy initiatives via cord blood stem cell sourcing and processing; CCEL's core business is cord blood banking and tissue storage, which aligns with cell therapy ecosystems.
|
$35.77M |
$4.43
+0.35%
|
|
Provides R&D services and contract-like research capabilities leveraging its patents (CRO-like revenue).
|
$35.75M |
$2.02
|
|
Mural Oncology is focused on developing oncology immunotherapies and engineered cytokine therapeutics (nemvaleukin and related programs).
|
$35.75M |
$2.07
-0.48%
|
|
OnKure Therapeutics is a biotechnology company focused on oncology with a pipeline of targeted cancer therapies (lead PI3Kα mutant inhibitor).
|
$35.13M |
$2.60
+0.58%
|
|
Direct placenta-derived cell therapy and MAIT-cell immunotherapy pipelines powering Pluri's core business.
|
$34.35M |
$4.39
-2.55%
|
|
IGC-AD1 is the lead Alzheimer’s disease therapeutic candidate in Phase 2, directly mapped to Alzheimer’s Disease Therapeutics.
|
$33.48M |
$0.40
-4.29%
|
|
Rafael is focused on Trappsol Cyclo for Niemann-Pick Disease Type C1, a rare disease, making Rare Diseases a core investable theme.
|
$33.38M |
$1.34
-1.47%
|
|
IMG-007 is a monoclonal antibody targeting OX40 developed for immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$32.01M |
$7.96
-2.21%
|
|
CEL-SCI develops oncology-focused immunotherapy products, with Multikine as the lead candidate for cancer treatment.
|
$31.77M |
$10.47
+2.25%
|
|
Product pipeline includes recombinant vaccine antigens (e.g., Mpox ferritin antigen) and vaccine-related proteins, tying to vaccines development/production.
|
$31.60M |
$1.05
-7.08%
|
|
Exicure's core biotechnology focus is on oncology, anchored by the GPCR USA lead asset (GPC-100.00).
|
$31.27M |
$4.95
-13.91%
|
|
TENX's core program centers on levosimendan (TNX-103) for PH-HFpEF, a cardiovascular drug, aligning with the Cardiovascular Drugs tag.
|
$30.95M |
$7.46
-4.85%
|
|
Kezar's lead candidate zetomipzomib targets immune-mediated diseases (autoimmune hepatitis), aligning with Immunology Therapeutics.
|
$30.83M |
$4.22
-5.17%
|
|
In-house contract manufacturing capabilities via Cana Laboratories Cyprus (and DolCas) underpin higher-margin manufacturing revenue.
|
$30.76M |
$1.07
-8.15%
|
|
CID-103 is a fully human anti-CD38 monoclonal antibody developed for autoimmune diseases and organ transplant rejection, placing CASI in the Immunology Therapeutics space.
|
$30.28M |
$1.98
-3.41%
|
Showing page 6 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
